FDA harmonization task force report
Executive Summary
Has been completed and will be available within two weeks from the National Technical Information Services (NTIS). In Dec. 9 "Talk Paper," FDA said the report "makes recommendations for future agency activities and calls for continuing discussions" in the GATT and NAFTA talks, with the European community and "in other forums," to "encourage international cooperation." FDA says the report also "addresses the need for adequate resources to carry out international programs and cites increased costs, such as those required for conducting foreign inspections, as a driving force" for efforts to harmonize manufacturing standards and enforcement. FDA points out that it has Memoranda of Understanding on GMP inspections with Canada, Sweden and Switzerland and the agency "is exploring the possibility of agreements with Japan, Australia, the EC and others".
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth